ARTICLE | Emerging Company Profile

Concurrent: The jump from computing

June 14, 2004 7:00 AM UTC

Until recently, Concurrent Pharmaceuticals Inc. has relied on its Concentric computational platform to identify and optimize small molecule candidates to treat cardiovascular and renal diseases. However, the company has taken a big step toward a product focus by acquiring a portfolio of compounds that are in or near the clinic in diabetes, cancer and skin disorders.

CEO Jeffrey Hatfield contends that, while the traditional method of drug discovery is to identify millions of active molecules and screen hundreds, this approach will come up with only a handful of viable candidates. Instead, Concurrent (Fort Washington, Penn.) uses a computational approach that it hopes will save both time and money...